Showing results (201-210 of 280) with videos related to
Sort By:
Pageof 28
Blood Advances|January 26, 2022
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapyJurjen Versluis, Manu Pandey, Yael Flamand, et al.Blood Cancer Journal|November 1, 2024
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimenShai Shimony, Hari S Raman, Yael Flamand, et al.Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.Proceedings of the National Academy of Sciences of the United States of America|September 28, 2004
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderJing Chen, Daniel J Deangelo, Jeffery L Kutok, et al.Blood|February 28, 2014
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AMLSophia Adamia, Michal Bar-Natan, Benjamin Haibe-Kains, et al.Open Forum Infectious Diseases|August 14, 2015
Epidemiologic Investigation of a Cluster of Neuroinvasive Bacillus cereus Infections in 5 Patients With Acute Myelogenous LeukemiaChanu Rhee, Michael Klompas, Fiona B Tamburini, et al.Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.Cancer Research Communications|June 4, 2026
CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX StudyClaire Roddie, William Day, Meera Raymond, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2026
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Giovanni Marconi, Pau Montesinos, et al.Pageof 28